Image Article - (2025) Volume 11, Issue 2
Aurelio Castrellon Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, USA E-mail: acastrellon@mhs.net
Abstract
The addition of targeted agents to the armamentarium of therapies for Triple-Negative Breast Cancer (TNBC), like in other types of breast cancer, has improved the overall survival of patients affected with advanced disease. Inhibitors of the poly adenosine diphosphate-ribose polymerase (PARP inhibitors) block an important enzyme involved in the repair mechanism of DNA damage in cells. Following the findings of the olympiad phase 3 clinical trial, Olaparib was the first targeted therapy to be approved in the treatment of metastatic TNBC.
Received: 05-Mar-2024, Manuscript No. OCCRS-24-128896; Editor assigned: 07-Mar-2024, Pre QC No. OCCRS-24-128896 (PQ); Reviewed: 21-Mar-2024, QC No. OCCRS-24-128896; Revised: 18-Mar-2025, Manuscript No. OCCRS-24-128896 (R); Published: 25-Mar-2025, DOI: 10.35248/2471-8556.25.11(1).001-008
Copyright: ©: 2025 Castrellon A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.